ArticleDiscover oncology2026
Roles of m6A regulators in shaping methylation patterns and tumor microenvironment immune infiltration in colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Recent studies have demonstrated that immune responses are subject to epigenetic regulation. However, the functional roles of RNA N6-methyladenosine (m6A) modification in infiltrating cells within the tumor microenvironment (TME) remain incompletely understood. To systematically characterize m6A modification patterns, we conducted a comprehensive analysis across 1,195 colorectal cancer samples, focusing on 27 m6A regulators. We further associated the three identified modification patterns with the characteristics of immune cell infiltration in the TME. To quantify m6A modification patterns at the individual tumor level, we developed an m6A score using principal component analysis (PCA). Analysis of immune cell infiltration in the TME revealed that the three distinct m6A modification patterns were significantly associated with three tumor immune phenotypes: immune-excluded, immune-inflamed, and immune-desert. Furthermore, univariate and multivariate Cox regression analyses indicated that the m6A score served as an independent and reliable prognostic biomarker for colorectal cancer (CRC) patients. Collectively, these findings suggest that m6A modification is associated with immune modulation and correlates with TME heterogeneity. Characterization of m6A modification patterns in CRC patients may enhance our understanding of immune cell infiltration within the TME and inform immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.